Pseudohypoparathyroidism (PHP) is a group of disorders caused by impaired signaling at the GNAS locus, producing resistance to parathyroid hormone and, in many patients, additional endocrine and developmental abnormalities. The phenotype reflects both parent-of-origin effects (imprinting) and tissue-specific dependence on Gs alpha signaling.
Ask a research question about Pseudohypoparathyroidism. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Pseudohypoparathyroidism
creation_date: '2026-02-10T22:32:16Z'
updated_date: '2026-02-11T07:18:02Z'
description: >-
Pseudohypoparathyroidism (PHP) is a group of disorders caused by impaired
signaling at the GNAS locus, producing resistance to parathyroid hormone and,
in many patients, additional endocrine and developmental abnormalities. The
phenotype reflects both parent-of-origin effects (imprinting) and tissue-specific
dependence on Gs alpha signaling.
category: Genetic
parents:
- Endocrine Disorder
- Calcium-Phosphate Metabolism Disorder
disease_term:
preferred_term: pseudohypoparathyroidism
term:
id: MONDO:0019992
label: pseudohypoparathyroidism
has_subtypes:
- name: PHP1A
description: >-
Usually caused by maternally inherited inactivating GNAS variants with
parathyroid hormone resistance, additional hormone resistance, and Albright
hereditary osteodystrophy features.
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: While maternal mutations result in PHP type 1A, which consists of PTH resistance and AHO, paternal mutations lead to pseudo-pseudohypoparathyroidism (PPHP), that is, AHO without hormone resistance.
explanation: Confirms maternal-allele mutations classically produce PHP1A with PTH resistance and AHO.
- name: PHP1B
description: >-
Usually caused by GNAS methylation defects (often including STX16-related
imprinting abnormalities) with predominant renal PTH resistance and less
pronounced Albright hereditary osteodystrophy.
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Epigenetic alterations of GNAS cause PHP type 1B (PHP1B), defined by PTH resistance in the absence of AHO.
explanation: Supports the subtype definition of PHP1B as an epigenetic GNAS disorder with predominant PTH resistance.
- name: Pseudopseudohypoparathyroidism
description: >-
Usually caused by paternally inherited inactivating GNAS variants and
characterized by Albright hereditary osteodystrophy features with limited or
absent hormone resistance.
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: While maternal mutations result in PHP type 1A, which consists of PTH resistance and AHO, paternal mutations lead to pseudo-pseudohypoparathyroidism (PPHP), that is, AHO without hormone resistance.
explanation: Directly distinguishes paternal-allele PPHP from maternal-allele PHP1A.
prevalence:
- population: Japan period prevalence
percentage: 3.4 per million
notes: >-
A nationwide Japanese survey provides one of the few population-based
prevalence estimates for pseudohypoparathyroidism.
evidence:
- reference: PMID:10695258
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Using these data, the period prevalence of the diseases were 7.2 (5.5-8.8) per million population in idiopathic hypoparathyroidism, and 3.4 (2.6-4.2) in pseudohypoparathyroidism (95% confidence intervals in parentheses)."
explanation: This nationwide epidemiologic survey directly estimates pseudohypoparathyroidism prevalence in Japan.
- reference: PMID:32481259
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Pseudohypoparathyroidism (PHP) indicates a group of rare disorders characterized by end-organ resistance to various hormones, primarily parathyroid hormone (PTH)."
explanation: This modern case report reinforces that PHP remains a rare disorder in current clinical practice.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_imprinting_model
hypothesis_label: Canonical GNAS Imprinting Model
status: CANONICAL
description: >-
Parent-of-origin-specific GNAS expression explains subtype stratification:
maternal alterations more often produce hormone resistance, while paternal
coding variants favor AHO-predominant phenotypes.
notes: >-
Retained as CANONICAL per the 2026 falcon hypothesis-search report
(kb/hypotheses/Pseudohypoparathyroidism/canonical_imprinting_model;
openscientist timed out on this hypothesis). The parent-of-origin
framework is robustly supported by tissue-specific Gnas knockout
mouse models and the molecular control region (1A DMR). Key
refinements: (1) the STX16-ICR boundary establishes imprinting via
OCT4-dependent chromatin conformation during embryogenesis; (2) the
iPPSD nomenclature integrates GNAS-imprinting disorders with other
cAMP-pathway disorders (acrodysostosis via PRKAR1A/PDE4D; PTHLH;
TRPS1) sharing brachydactyly phenotypes; (3) tissue distribution of
imprinting (renal proximal tubule, thyroid, pituitary, ovary, DMH
hypothalamus) underlies the PHP1A-specific endocrine resistance and
obesity pattern absent in PPHP.
applies_to_subtypes:
- PHP1A
- PHP1B
- Pseudopseudohypoparathyroidism
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Thus, genomic imprinting plays a key role in the phenotypes associated with GNAS alterations.
explanation: Supports imprinting as the organizing principle for subtype-specific phenotype patterns.
- hypothesis_group_id: endocrine_resistance_model
hypothesis_label: Endocrine Resistance Model
status: CANONICAL
description: >-
Impaired Gs alpha signaling in hormone-responsive tissues causes PTH-centered
mineral metabolism abnormalities and variable resistance to additional
endocrine axes such as TSH and GH pathways.
notes: >-
Retained as CANONICAL per the 2026 falcon hypothesis-search report
(kb/hypotheses/Pseudohypoparathyroidism/endocrine_resistance_model;
openscientist timed out). Multi-axis resistance pattern (PTH, TSH,
GHRH, gonadotropin) is supported by tissue-specific Gsα-mediated
GPCR signaling failure in imprinted tissues. Key qualifications:
(1) PHP1A and PHP1B differ in non-PTH endocrine resistance — PHP1A
typically has TSH/gonadotropin resistance while PHP1B is
predominantly PTH-resistant; (2) novel ACRDYS-like resistance
syndromes (PRKAR1A, PDE4D mutations) reproduce the phenotype with
different molecular lesions in the same cAMP signaling cascade.
applies_to_subtypes:
- PHP1A
- PHP1B
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: specific features, such as PTH resistance, TSH resistance, growth hormone deficiency
explanation: Consensus guidance supports a multiaxis endocrine resistance framework.
- hypothesis_group_id: aho_mesenchymal_model
hypothesis_label: AHO Mesenchymal Differentiation Model
status: CANONICAL
description: >-
Altered GNAS-dependent signaling in bone and mesenchymal lineages drives
brachydactyly, ectopic ossification, and related AHO structural phenotypes.
notes: >-
Retained as CANONICAL per the 2026 falcon hypothesis-search report
(kb/hypotheses/Pseudohypoparathyroidism/aho_mesenchymal_model;
openscientist timed out). The chondrocyte-specific (PMID:15765186)
and osteoblast-specific (PMID:15797856) Gsα knockout mouse studies
establish biallelic Gsα expression in bone/cartilage as the
mechanistic basis for AHO features in both PHP1A and PPHP. α-SMA-
expressing dermal sheath cells were recently identified as the
cellular source of heterotopic subcutaneous ossifications
(PMID:40256763). AHO-like brachydactyly also arises from mutations
in other PTHrP→Gsα→cAMP→PKA pathway nodes (PRKAR1A, PDE4D, PTHLH,
TRPS1), so the model is pathway-correct but not GNAS-exclusive.
applies_to_subtypes:
- PHP1A
- Pseudopseudohypoparathyroidism
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: resistance to PTH, ectopic ossifications, brachydactyly and early-onset obesity.
explanation: Supports the core AHO morphologic feature set grouped in this model.
- hypothesis_group_id: neurohypocalcemia_model
hypothesis_label: Neurohypocalcemia Symptom Model
status: CANONICAL
description: >-
Neurologic symptoms, including tetany and seizures, arise primarily from
downstream hypocalcemia and associated mineral imbalance.
notes: >-
Retained as CANONICAL per the 2026 falcon hypothesis-search report
(kb/hypotheses/Pseudohypoparathyroidism/neurohypocalcemia_model;
openscientist timed out). Hypocalcemia from impaired renal-tubular
PTH responsiveness is the proximal driver of tetany, seizures, and
Trousseau/Chvostek signs in PHP1A and PHP1B. Key qualification:
intracerebral calcifications (basal ganglia, dentate) develop
independently of acute calcium status and may reflect chronic
phosphate-calcium dysregulation. Cognitive impairment in PHP1A is
partly dissociable from calcium status — linked to early-onset Gsα
haploinsufficiency in CNS development rather than acute
neurohypocalcemia alone.
applies_to_subtypes:
- PHP1A
- PHP1B
evidence:
- reference: PMID:38423572
reference_title: "Epileptic seizures and abnormal tooth development as primary presentation of pseudohypoparathyroidism type 1B."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: This case demonstrates the importance of screening for hypocalcaemia in patients with de novo epileptic seizures.
explanation: Supports neurologic manifestations as a downstream consequence of hypocalcemia in PHP.
- hypothesis_group_id: neuroendocrine_obesity_model
hypothesis_label: GNAS-Related Neuroendocrine Obesity Model
status: EMERGING
description: >-
Early-onset obesity may reflect disrupted Gs alpha-dependent GPCR signaling
in energy-homeostasis pathways, superimposed on classic PHP endocrine and
skeletal mechanisms.
notes: >-
Retained as EMERGING per the 2026 falcon hypothesis-search report
(kb/hypotheses/Pseudohypoparathyroidism/neuroendocrine_obesity_model;
openscientist timed out). The most rigorous mechanistic finding
(PMID:27991864) demonstrates that maternal Gsα loss in the
dorsomedial nucleus of the hypothalamus (DMH) impairs MC4R/Gsα
signaling, reducing energy expenditure and BAT activation without
causing hyperphagia. This DMH-imprinting model explains why obesity
is specific to PHP1A (maternal mutations) and absent in PPHP
(paternal mutations). Additional candidate contributions: TSH/GH
resistance contributing to metabolic-rate suppression, and
melanocortin/PCSK1 pathway dysregulation.
applies_to_subtypes:
- PHP1A
- PHP1B
evidence:
- reference: PMID:38103632
reference_title: "The role of genetic and epigenetic GNAS alterations in the development of early-onset obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Genetic or epigenetic alterations in GNAS are known to cause pseudohypoparathyroidism in its different subtypes and have been recently associated with isolated, early-onset, severe obesity.
explanation: Supports obesity-specific mechanistic superimposition on canonical PHP pathophysiology.
pathophysiology:
- name: GNAS Imprinting-Dependent Signaling Defect
description: >-
Pathogenic variants or epigenetic abnormalities at the GNAS locus reduce
functional Gs alpha signaling. Because GNAS expression is parent-of-origin
dependent in selected tissues, maternal defects disproportionately impair
receptor signaling in renal proximal tubules and endocrine targets.
genes:
- preferred_term: GNAS
term:
id: hgnc:4392
label: GNAS
biological_processes:
- preferred_term: genomic imprinting
term:
id: GO:0071514
label: genomic imprinting
- preferred_term: adenylate cyclase-modulating G protein-coupled receptor signaling pathway
term:
id: GO:0007188
label: adenylate cyclase-modulating G protein-coupled receptor signaling pathway
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Thus, genomic imprinting plays a key role in the phenotypes associated with GNAS alterations.
explanation: Establishes imprinting as the upstream mechanism determining subtype-specific manifestations.
- reference: PMID:25905388
reference_title: "Hypoparathyroidism and Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: PHP1A and PHP1B are caused by maternally-inherited changes at the imprinted GNAS complex gene
explanation: Supports maternal-allele GNAS alterations as a core etiologic mechanism.
downstream:
- target: Renal PTH Resistance
description: Defective Gs alpha signaling blunts cAMP response to PTH in proximal renal tubules.
hypothesis_groups:
- canonical_imprinting_model
causal_link_type: DIRECT
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: including the proximal renal tubule, where PTH exerts critical actions.
explanation: Supports direct imprinting-sensitive disruption of renal PTH signaling.
- target: Multihormone Resistance
description: Resistance may extend to other Gs alpha-coupled endocrine pathways including TSH and GHRH.
hypothesis_groups:
- canonical_imprinting_model
- endocrine_resistance_model
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- TSH resistance
- growth hormone deficiency
- target: AHO Developmental Tissue Effects
description: Reduced GNAS signaling in bone and adipose lineages drives Albright hereditary osteodystrophy features.
hypothesis_groups:
- canonical_imprinting_model
- aho_mesenchymal_model
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- altered Gs alpha-cAMP signaling in mesenchymal lineages
- name: Renal PTH Resistance
description: >-
Kidney target tissues fail to mount a normal phosphaturic and calcium-preserving
response to PTH. This produces biochemical findings of hypocalcemia and
hyperphosphatemia despite elevated circulating PTH.
cell_types:
- preferred_term: epithelial cell of proximal tubule
term:
id: CL:0002306
label: epithelial cell of proximal tubule
locations:
- preferred_term: kidney
term:
id: UBERON:0002113
label: kidney
- preferred_term: proximal tubule
term:
id: UBERON:0004134
label: proximal tubule
biological_processes:
- preferred_term: response to parathyroid hormone
term:
id: GO:0071107
label: response to parathyroid hormone
- preferred_term: phosphate ion homeostasis
term:
id: GO:0055062
label: phosphate ion homeostasis
- preferred_term: calcium ion homeostasis
term:
id: GO:0055074
label: calcium ion homeostasis
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: including the proximal renal tubule, where PTH exerts critical actions.
explanation: Identifies proximal renal tubule as the key imprinting-sensitive site for PTH resistance.
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Confirms the biochemical triad resulting from end-organ PTH resistance.
downstream:
- target: Hyperphosphatemia
description: Reduced renal phosphate excretion causes chronic phosphate retention.
hypothesis_groups:
- endocrine_resistance_model
causal_link_type: DIRECT
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Directly supports hyperphosphatemia as a primary biochemical output of PTH resistance.
- target: Hypocalcemia
description: Impaired renal response to PTH contributes to persistent low serum calcium.
hypothesis_groups:
- endocrine_resistance_model
causal_link_type: DIRECT
- target: Elevated Parathyroid Hormone
description: Secondary hyperparathyroidism develops as parathyroid output rises to compensate.
hypothesis_groups:
- endocrine_resistance_model
causal_link_type: DIRECT
- target: Mineral Ion Imbalance and Neuromuscular Excitability
description: Severe calcium-phosphate imbalance destabilizes neuromuscular function.
hypothesis_groups:
- neurohypocalcemia_model
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- hypocalcemia
- hyperphosphatemia
- name: Mineral Ion Imbalance and Neuromuscular Excitability
description: >-
Hypocalcemia increases neuronal and neuromuscular excitability, lowering seizure
threshold and producing intermittent acute neurologic symptoms.
biological_processes:
- preferred_term: calcium ion homeostasis
term:
id: GO:0055074
label: calcium ion homeostasis
evidence:
- reference: PMID:35410271
reference_title: "Clinical and genetic analysis of pseudohypoparathyroidism complicated by hypokalemia: a case report and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Laboratory assessments of the patient revealed hypokalemia, hypocalcemia and hyperphosphatemia despite elevated PTH levels.
explanation: Demonstrates clinically relevant mineral imbalance expected from PTH resistance.
downstream:
- target: Tetany
description: Increased neuromuscular excitability causes cramps, spasms, and carpopedal signs.
hypothesis_groups:
- neurohypocalcemia_model
causal_link_type: DIRECT
- target: Seizures
description: Marked hypocalcemia can precipitate focal or generalized seizures.
hypothesis_groups:
- neurohypocalcemia_model
causal_link_type: DIRECT
evidence:
- reference: PMID:38423572
reference_title: "Epileptic seizures and abnormal tooth development as primary presentation of pseudohypoparathyroidism type 1B."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: We describe a case in which epileptic seizures and abnormalities in dental development were the main clinical manifestation of PHP type 1B.
explanation: Demonstrates seizure phenotype as a neurologic downstream consequence in PHP.
- name: Multihormone Resistance
description: >-
In affected subtypes, resistance extends beyond PTH to additional Gs alpha-coupled
hormonal pathways, especially thyroid and growth axes.
biological_processes:
- preferred_term: hormone-mediated signaling pathway
term:
id: GO:0009755
label: hormone-mediated signaling pathway
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: specific features, such as PTH resistance, TSH resistance, growth hormone deficiency
explanation: Supports that endocrine resistance in PHP commonly extends beyond PTH signaling.
downstream:
- target: Hypothyroidism
description: TSH resistance can lead to biochemical and clinical hypothyroidism.
hypothesis_groups:
- endocrine_resistance_model
causal_link_type: DIRECT
- target: Short Stature
description: Combined endocrine resistance and skeletal effects can limit linear growth.
hypothesis_groups:
- endocrine_resistance_model
- aho_mesenchymal_model
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- growth hormone deficiency
- name: AHO Developmental Tissue Effects
description: >-
Albright hereditary osteodystrophy reflects altered developmental signaling in
bone, adipose tissue, and other mesenchymal lineages, partially independent
of biochemical severity.
cell_types:
- preferred_term: osteoblast
term:
id: CL:0000062
label: osteoblast
- preferred_term: adipocyte
term:
id: CL:0000136
label: adipocyte
locations:
- preferred_term: bone element
term:
id: UBERON:0001474
label: bone element
biological_processes:
- preferred_term: endochondral ossification
term:
id: GO:0001958
label: endochondral ossification
- preferred_term: ossification
term:
id: GO:0001503
label: ossification
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: resistance to PTH, ectopic ossifications, brachydactyly and early-onset obesity.
explanation: Defines the core AHO-associated developmental phenotype cluster.
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: While maternal mutations result in PHP type 1A, which consists of PTH resistance and AHO, paternal mutations lead to pseudo-pseudohypoparathyroidism (PPHP), that is, AHO without hormone resistance.
explanation: Supports parent-of-origin partitioning of AHO features versus hormone resistance.
downstream:
- target: Brachydactyly
description: Disordered endochondral growth shortens metacarpals and other tubular bones.
hypothesis_groups:
- aho_mesenchymal_model
causal_link_type: DIRECT
- target: Subcutaneous Ossifications
description: Ectopic dermal and subcutaneous ossification forms firm palpable nodules.
hypothesis_groups:
- aho_mesenchymal_model
causal_link_type: DIRECT
- target: Obesity
description: Altered GNAS-dependent metabolic regulation contributes to early-onset adiposity.
hypothesis_groups:
- aho_mesenchymal_model
- neuroendocrine_obesity_model
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- MC4R-related appetite and energy homeostasis signaling
- target: Developmental Delay
description: Some patients show neurodevelopmental effects with learning or global delay.
hypothesis_groups:
- aho_mesenchymal_model
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- name: Chiari Malformation Type 1
category: Neurological
subtype: PHP1A
frequency: OCCASIONAL
description: >-
Chiari malformation type 1 (CM1) occurs at approximately 10-fold the
general population prevalence in PHP1A, with 10.8% prevalence in
imaging-confirmed cohorts (21.7% when including low-lying cerebellar
tonsils). Mouse Gnas E1+/-m models show smaller cranial vault,
increased cranial dome angle, hyperostosis, and premature spheno-
occipital synchondrosis closure, providing a developmental etiology.
CM1 prevalence is independent of GH deficiency status, and clinical
threshold for brain imaging should be low. Surfaced by the 2026
falcon deep-research review of the AHO mesenchymal differentiation
model.
phenotype_term:
preferred_term: Chiari type I malformation
term:
id: HP:0007099
label: Chiari type I malformation
evidence:
- reference: PMID:36662765
reference_title: "Prevalence of Chiari malformation type 1 is increased in pseudohypoparathyroidism type 1A and associated with aberrant bone development."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "prevalence of CM1 is at least 10-fold higher"
explanation: >
Krishnan et al. (2023) demonstrate that PHP1A patients have at
least 10-fold higher CM1 prevalence than the general population
(10.8% by imaging; 21.7% with LLCT), correlating with mouse-model
evidence of aberrant cranial base development.
- name: Basal Ganglia Calcification
category: Neurological
frequency: OCCASIONAL
description: >-
Intracranial calcifications (basal ganglia, globus pallidus, frontal
cortex) develop in PHP patients and are frequent in PHP1B cohorts.
Calcifications can develop independently of acute calcium status and
may persist even after calcium normalization, reflecting chronic
calcium-phosphate dysregulation. Surfaced by the 2026 falcon deep-
research review of the neurohypocalcemia model
(kb/hypotheses/Pseudohypoparathyroidism/neurohypocalcemia_model).
phenotype_term:
preferred_term: Basal ganglia calcification
term:
id: HP:0002135
label: Basal ganglia calcification
evidence:
- reference: PMID:35410271
reference_title: "Clinical and genetic analysis of pseudohypoparathyroidism complicated by hypokalemia: a case report and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "CT scanning of the brain revealed globus pallidus calcification"
explanation: >
CT-confirmed globus pallidus calcification documented in a PHP1B
patient, supporting basal ganglia calcification as a phenotype
that develops in the setting of chronic mineral dysregulation.
- name: Hypocalcemia
category: Biochemical
frequency: VERY_FREQUENT
diagnostic: true
description: Low serum calcium with elevated PTH due to end-organ resistance.
phenotype_term:
preferred_term: Hypocalcemia
term:
id: HP:0002901
label: Hypocalcemia
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Confirms hypocalcemia as a defining biochemical consequence of PHP.
- name: Hyperphosphatemia
category: Biochemical
frequency: VERY_FREQUENT
diagnostic: true
description: Elevated serum phosphate from impaired renal phosphate excretion.
phenotype_term:
preferred_term: Hyperphosphatemia
term:
id: HP:0002905
label: Hyperphosphatemia
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Confirms hyperphosphatemia as part of the hallmark PHP biochemical triad.
- name: Elevated Parathyroid Hormone
category: Biochemical
frequency: VERY_FREQUENT
diagnostic: true
description: Compensatory PTH elevation despite hypocalcemia.
phenotype_term:
preferred_term: Elevated circulating parathyroid hormone level
term:
id: HP:0003165
label: Elevated circulating parathyroid hormone level
evidence:
- reference: PMID:35410271
reference_title: "Clinical and genetic analysis of pseudohypoparathyroidism complicated by hypokalemia: a case report and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Laboratory assessments of the patient revealed hypokalemia, hypocalcemia and hyperphosphatemia despite elevated PTH levels.
explanation: Supports elevation of PTH despite biochemical hypocalcemia-hyperphosphatemia.
- name: Tetany
category: Neurological
frequency: OCCASIONAL
description: Neuromuscular irritability with spasm during hypocalcemic episodes.
phenotype_term:
preferred_term: Tetany
term:
id: HP:0001281
label: Tetany
evidence:
- reference: PMID:35410271
reference_title: "Clinical and genetic analysis of pseudohypoparathyroidism complicated by hypokalemia: a case report and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Seven months after delivery, she experienced tetany and dysphonia with diarrhea.
explanation: Documents tetany as an acute symptomatic manifestation in PHP.
- name: Seizures
category: Neurological
frequency: OCCASIONAL
description: Hypocalcemia-associated seizure episodes, often in childhood.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:38423572
reference_title: "Epileptic seizures and abnormal tooth development as primary presentation of pseudohypoparathyroidism type 1B."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: We describe a case in which epileptic seizures and abnormalities in dental development were the main clinical manifestation of PHP type 1B.
explanation: Supports seizures as a clinically important presentation in PHP1B.
- name: Brachydactyly
category: Skeletal
frequency: FREQUENT
diagnostic: true
description: Shortened metacarpals and digits, especially in the fourth and fifth rays.
phenotype_term:
preferred_term: Brachydactyly
term:
id: HP:0001156
label: Brachydactyly
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: resistance to PTH, ectopic ossifications, brachydactyly and early-onset obesity.
explanation: Consensus statement lists brachydactyly among major diagnostic criteria.
- name: Short Stature
category: Growth
frequency: FREQUENT
description: Reduced linear growth from endocrine and skeletal mechanisms.
phenotype_term:
preferred_term: Short stature
term:
id: HP:0004322
label: Short stature
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: include short bones, short stature, a stocky build, early-onset obesity and ectopic ossifications
explanation: Identifies short stature as part of the core physical phenotype in PHP-related disorders.
- name: Obesity
category: Metabolic
frequency: FREQUENT
description: Early-onset weight gain and increased adiposity.
phenotype_term:
preferred_term: Obesity
term:
id: HP:0001513
label: Obesity
evidence:
- reference: PMID:38103632
reference_title: "The role of genetic and epigenetic GNAS alterations in the development of early-onset obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Genetic or epigenetic alterations in GNAS are known to cause pseudohypoparathyroidism in its different subtypes and have been recently associated with isolated, early-onset, severe obesity.
explanation: Supports mechanistic and clinical linkage between GNAS defects and early-onset obesity.
- name: Subcutaneous Ossifications
category: Skeletal
frequency: FREQUENT
description: Ectopic ossification in skin and soft tissues.
phenotype_term:
preferred_term: Subcutaneous ossification
term:
id: HP:0034282
label: Subcutaneous ossification
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: subcutaneous and/or deeper ectopic ossifications and neurocognitive impairment.
explanation: Consensus guidance highlights subcutaneous ectopic ossifications as a monitored feature.
- name: Round Face
category: Craniofacial
subtype: PHP1A
frequency: FREQUENT
description: >-
Rounded facial appearance is a classic feature of Albright hereditary
osteodystrophy, part of the AHO triad alongside short stature and
subcutaneous ossifications. Present in PHP1A; absent in PHP1B which
lacks AHO features. Surfaced by the GeneReviews baseline check
requested during ai4c-agent review of the 2026 deep-research PR.
phenotype_term:
preferred_term: Round face
term:
id: HP:0000311
label: Round face
evidence:
- reference: PMID:29072892
reference_title: "Disorders of GNAS Inactivation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "short stature, round"
explanation: >
GeneReviews defines the AHO phenotype as including short stature,
round facies, and subcutaneous ossifications — the classic AHO
triad characteristic of PHP1A.
- name: Hypothyroidism
category: Endocrine
frequency: OCCASIONAL
description: TSH resistance causing low thyroid hormone effect.
phenotype_term:
preferred_term: Hypothyroidism
term:
id: HP:0000821
label: Hypothyroidism
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: specific features, such as PTH resistance, TSH resistance, growth hormone deficiency
explanation: TSH resistance provides mechanistic support for hypothyroid manifestations in PHP.
- name: Developmental Delay
category: Neurological
frequency: OCCASIONAL
description: Variable neurodevelopmental impairment across disease subtypes.
phenotype_term:
preferred_term: Global developmental delay
term:
id: HP:0001263
label: Global developmental delay
evidence:
- reference: PMID:29959430
reference_title: "Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: subcutaneous and/or deeper ectopic ossifications and neurocognitive impairment.
explanation: Neurocognitive impairment in consensus guidance supports developmental and cognitive phenotype burden.
biochemical:
- name: Parathyroid Hormone
presence: Elevated
context: Elevated PTH with hypocalcemia and hyperphosphatemia supports hormone resistance.
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Directly supports elevated PTH in the context of end-organ resistance.
- name: Serum Calcium
presence: Decreased
context: Persistent or recurrent hypocalcemia is common at presentation.
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Supports hypocalcemia as a central biochemical finding.
- name: Serum Phosphate
presence: Elevated
context: Renal phosphate retention leads to chronic hyperphosphatemia.
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: It is characterized by hypocalcemia, hyperphosphatemia, and an elevated parathyroid hormone concentration secondary to the resistance of target tissues to the biological actions of parathyroid hormone.
explanation: Supports persistent hyperphosphatemia in PHP.
genetic:
- name: GNAS
gene_term:
preferred_term: GNAS
term:
id: hgnc:4392
label: GNAS
association: Loss-of-Function Variant or Imprinting Defect
evidence:
- reference: PMID:37014531
reference_title: "Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Pseudohypoparathyroidism (PHP) is a disorder caused by mutations and/or epigenetic changes at the complex GNAS locus.
explanation: Supports both genetic and epigenetic GNAS mechanisms in disease causation.
inheritance:
- name: Autosomal dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
expressivity: VARIABLE
parent_of_origin_effect: Maternal inheritance typically causes hormone resistance; paternal inheritance more often causes AHO without marked PTH resistance.
evidence:
- reference: PMID:40972900
reference_title: "Imprinting and skeletal disorders: lessons from pseudohypoparathyroidism and related disorders."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: While maternal mutations result in PHP type 1A, which consists of PTH resistance and AHO, paternal mutations lead to pseudo-pseudohypoparathyroidism (PPHP), that is, AHO without hormone resistance.
explanation: Documents the parent-of-origin effect that modifies expression of dominantly inherited GNAS defects.
notes: >-
Parent-of-origin and epigenetic context at the GNAS locus strongly determine
clinical subtype and severity.
treatments:
- name: Calcium and Active Vitamin D Replacement
description: >-
Calcium supplementation combined with active vitamin D (calcitriol or
alfacalcidol) to correct hypocalcemia and hyperphosphatemia. Standard
of care for PHP1A and PHP1B; correction of hypocalcemia resolves
tetany, seizures, and dyskinesias.
target_phenotypes:
- preferred_term: Hypocalcemia
term:
id: HP:0002901
label: Hypocalcemia
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: calcium
term:
id: CHEBI:29108
label: calcium(2+)
- preferred_term: calcitriol
term:
id: CHEBI:17823
label: calcitriol
evidence:
- reference: PMID:25905388
reference_title: "Hypoparathyroidism and Pseudohypoparathyroidism."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Calcium and vitamin D are the standard therapy"
explanation: >
Endocrinology textbook reference frames calcium and active vitamin
D supplementation as the cornerstone of hypoparathyroidism / PHP
treatment for correcting hypocalcemia-driven neuromuscular
symptoms.
- name: Intravenous Calcium Gluconate (Acute Tetany)
description: >-
Intravenous calcium gluconate is the acute treatment for symptomatic
hypocalcemic tetany, seizures, and laryngospasm in PHP. Used
emergently before transition to oral calcium + active vitamin D
maintenance therapy.
target_phenotypes:
- preferred_term: Hypocalcemia
term:
id: HP:0002901
label: Hypocalcemia
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: calcium gluconate
term:
id: CHEBI:3309
label: calcium gluconate
evidence:
- reference: PMID:35410271
reference_title: "Clinical and genetic analysis of pseudohypoparathyroidism complicated by hypokalemia: a case report and review of the literature."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Tetany symptoms were relieved after intravenous calcium gluconate"
explanation: >
Case report of PHP1B with tetany symptoms documents resolution
after intravenous calcium gluconate supplementation, illustrating
the acute emergency use of IV calcium for symptomatic hypocalcemia.
references:
- reference: PMID:29072892
title: "Disorders of GNAS Inactivation."
tags:
- GeneReviews